AAPG
Ascentage Pharma Group Internat
Price Chart
Latest Quote
$14.67
-0.78 (-5.05%)
Current Price
| Previous Close | $15.45 |
| Open | $14.69 |
| Day High | $14.69 |
| Day Low | $14.54 |
| Volume | 3,160 |
Stock Information
Note: Financial values converted from CNY to USD
| Shares Outstanding | 93.39M |
| Total Debt | $314.69M |
| Cash Equivalents | $284.80M |
| Revenue | $96.55M |
| Net Income | $-220.66M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.37B |
| EPS (TTM) | $-2.26 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.65B |
| Sales | $96.55M |
| Income | $-220.66M |
| Book/sh | $0.89 |
| Cash/sh | $20.30 |
| Employees | 828 |
Financial Ratios
| Quick Ratio | 1.09 |
| Current Ratio | 1.22 |
| Debt/Eq | 370.18 |
Returns & Margins
| ROA | -28.04% |
| ROE | -236.63% |
| Gross Margin | 93.93% |
| Operating Margin | -248.91% |
| Profit Margin | -228.54% |
Ownership
| Institutional Ownership | 0.04% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -22.67 |
| P/S | 2.13 |
| P/B | 16.43 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $44.50 |
Technical Indicators
| SMA20 | $15.29 |
| SMA50 | $16.05 |
| SMA200 | $20.35 |
| RSI | 47.81 |
| ATR | 0.6558 |
| Shares Float | 71.53M |
| Short Float | 0.01% |
| Short Ratio | 1.45 |
| Volatility | 0.66 |
| Rel Volume | 0.41 |
Performance History
| Week | -7.85% |
| Month | -1.48% |
| Quarter | -19.88% |
| 6 Months | -36.22% |
| YTD | -44.37% |
| Year | -58.63% |
| 10 Years | -15.59% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $14.67 | 3,160 |
| 2026-10-26 | $15.45 | 3,100 |
| 2026-10-23 | $15.44 | 9,400 |
| 2026-10-22 | $14.92 | 18,800 |
| 2026-10-21 | $16.34 | 1,500 |
| 2026-10-20 | $15.92 | 4,800 |
| 2026-10-19 | $15.36 | 3,800 |
| 2026-10-16 | $15.37 | 15,100 |
| 2026-10-15 | $14.69 | 9,000 |
| 2026-10-14 | $14.85 | 3,400 |
| 2026-10-13 | $15.06 | 10,300 |
| 2026-10-12 | $15.31 | 4,600 |
| 2026-10-09 | $14.75 | 1,200 |
| 2026-10-08 | $14.55 | 12,000 |
| 2026-10-07 | $14.94 | 7,200 |
| 2026-10-06 | $16.09 | 14,500 |
| 2026-10-05 | $14.60 | 3,600 |
| 2026-10-02 | $15.36 | 9,000 |
| 2026-10-01 | $15.90 | 4,300 |
| 2026-09-30 | $16.31 | 13,700 |
| 2026-09-29 | $15.35 | 3,400 |
| 2026-09-28 | $14.89 | 4,800 |
About Ascentage Pharma Group Internat
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has strategic partnership with biotechnology and pharmaceutical companies; research institutions; and Peking University to build a collaborative system for hematological oncology. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
đ° Latest News
No news articles available at the moment. Check back later for updates on AAPG.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $7,319,254 | $4,350,004 | $4,568,065 | $3,290,060 |
| Cost Of Revenue | $7,319,254 | $4,350,004 | $4,568,065 | $3,290,060 |
| Total Revenue | $85,866,409 | $146,667,760 | $33,200,322 | $31,364,750 |
| Operating Revenue | $74,672,009 | $140,475,902 | $28,945,439 | $31,364,750 |
| Expenses | ||||
| Interest Expense | $8,086,805 | $9,640,005 | $14,366,456 | $7,894,619 |
| Total Expenses | $264,995,207 | $201,965,236 | $163,713,316 | $158,463,847 |
| Other Income Expense | $-9,932,547 | $163,022 | $511,800 | $851,904 |
| Other Non Operating Income Expenses | $-8,287,517 | $-664,204 | $-209,686 | $-457,659 |
| Net Non Operating Interest Income Expense | $4,195,956 | $-3,980,587 | $-9,519,308 | $-6,439,831 |
| Interest Expense Non Operating | $8,086,805 | $9,640,005 | $14,366,456 | $7,894,619 |
| Operating Expense | $257,675,953 | $197,615,232 | $159,145,250 | $155,173,787 |
| Other Operating Expenses | $-2,168,048 | $-1,356,974 | $-2,895,217 | $-5,024,827 |
| Selling And Marketing Expense | $52,891,028 | $29,313,810 | $29,222,428 | $23,544,165 |
| General And Administrative Expense | $36,834,225 | $27,986,748 | $27,082,049 | $25,514,492 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-185,870,744 | $-60,637,281 | $-138,439,917 | $-132,051,685 |
| Net Interest Income | $4,195,956 | $-3,980,587 | $-9,519,308 | $-6,439,831 |
| Interest Income | $12,282,761 | $5,659,418 | $4,847,148 | $1,454,787 |
| Normalized Income | $-184,601,749 | $-61,289,221 | $-138,996,178 | $-133,396,070 |
| Net Income From Continuing And Discontinued Operation | $-185,870,744 | $-60,637,281 | $-138,439,917 | $-132,051,685 |
| Net Income Common Stockholders | $-185,870,744 | $-60,637,281 | $-138,439,917 | $-132,051,685 |
| Net Income | $-185,870,744 | $-60,637,281 | $-138,439,917 | $-132,051,685 |
| Net Income Including Noncontrolling Interests | $-185,903,348 | $-60,674,223 | $-138,451,134 | $-132,051,685 |
| Net Income Continuous Operations | $-185,903,348 | $-60,674,223 | $-138,451,134 | $-132,051,685 |
| Pretax Income | $-184,865,389 | $-59,115,041 | $-139,520,501 | $-132,687,023 |
| Special Income Charges | $-2,692 | $-7,478 | $598 | $309,294 |
| Earnings From Equity Interest | $46,962 | $-42,027 | $160,928 | $-41,578 |
| Interest Income Non Operating | $12,282,761 | $5,659,418 | $4,847,148 | $1,454,787 |
| Operating Income | $-179,128,798 | $-55,297,477 | $-130,512,993 | $-127,099,096 |
| Gross Profit | $78,547,155 | $142,317,755 | $28,632,257 | $28,074,690 |
| Depreciation Amortization Depletion Income Statement | - | - | - | - |
| Depreciation And Amortization In Income Statement | - | - | - | - |
| Depreciation Income Statement | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-2.09 | $-0.80 | $-1.96 | $-2.00 |
| Basic EPS | $-2.09 | $-0.80 | $-1.96 | $-2.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $-422,998 | $217,313 | $4,296 | $6,756 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-162,152,489 | $-36,409,768 | $-111,776,193 | $-116,733,867 |
| Total Unusual Items | $-1,691,992 | $869,253 | $560,558 | $1,351,141 |
| Total Unusual Items Excluding Goodwill | $-1,691,992 | $869,253 | $560,558 | $1,351,141 |
| Reconciled Depreciation | $12,934,103 | $13,934,521 | $13,938,410 | $9,409,679 |
| EBITDA (Bullshit earnings) | $-163,844,481 | $-35,540,515 | $-111,215,635 | $-115,382,726 |
| EBIT | $-176,778,584 | $-49,475,037 | $-125,154,045 | $-124,792,405 |
| Diluted Average Shares | $13,315,876 | $11,294,236 | $10,555,295 | $9,859,443 |
| Basic Average Shares | $13,315,876 | $11,294,236 | $10,555,295 | $9,859,443 |
| Diluted NI Availto Com Stockholders | $-185,870,744 | $-60,637,281 | $-138,439,917 | $-132,051,685 |
| Minority Interests | $32,604 | $36,942 | $11,217 | $0 |
| Tax Provision | $1,037,959 | $1,559,182 | $-1,069,367 | $-635,338 |
| Gain On Sale Of Ppe | $-2,692 | $-7,478 | $598 | $309,294 |
| Gain On Sale Of Security | $-1,689,300 | $876,731 | $559,959 | $1,041,847 |
| Research And Development | $170,118,748 | $141,671,648 | $105,735,991 | $111,139,957 |
| Selling General And Administration | $89,725,253 | $57,300,558 | $56,304,476 | $49,058,657 |
| Other Gand A | $36,834,225 | $27,986,748 | $27,082,049 | $25,514,492 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $0 |
| Other Special Charges | - | - | $-598 | $-309,294 |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-10-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $184,534,110 | $24,453,650 | $-7,436,660 | $44,817,683 |
| Total Assets | $592,799,631 | $391,524,323 | $373,963,228 | $423,298,873 |
| Total Non Current Assets | $152,463,877 | $171,046,031 | $172,925,573 | $178,542,815 |
| Non Current Prepaid Assets | $103,198 | $364,781 | $448,685 | $972,152 |
| Non Current Deferred Assets | $9,244,114 | $11,181,986 | $8,950,076 | $8,120,307 |
| Non Current Deferred Taxes Assets | $4,779,546 | $6,616,015 | $8,950,076 | $8,120,307 |
| Investmentin Financial Assets | $598,247 | $170,650 | $291,795 | $390,207 |
| Financial Assets Designatedas Fair Value Through Profitor Loss Total | $598,247 | $170,650 | $291,795 | $390,207 |
| Goodwill And Other Intangible Assets | $13,554,784 | $15,059,675 | $16,472,734 | $16,301,935 |
| Other Intangible Assets | $9,861,506 | $11,366,396 | $12,779,456 | $12,608,656 |
| Current Assets | $440,335,755 | $220,478,293 | $201,037,654 | $244,756,058 |
| Restricted Cash | $850,259 | $3,684,155 | $3,669,797 | $2,482,875 |
| Prepaid Assets | $21,586,102 | $16,044,988 | $10,564,745 | $10,964,524 |
| Inventory | $4,280,159 | $986,659 | $2,417,965 | $1,413,060 |
| Receivables | $45,039,184 | $14,817,684 | $24,459,334 | $9,196,404 |
| Other Receivables | $217,612 | $917,861 | $992,642 | $97,066 |
| Taxes Receivable | $6,991,714 | $1,464,808 | $1,646,675 | $969,759 |
| Accounts Receivable | $37,829,858 | $12,435,015 | $21,820,017 | $8,129,580 |
| Cash Cash Equivalents And Short Term Investments | $368,580,051 | $184,944,807 | $159,925,813 | $220,699,195 |
| Cash And Cash Equivalents | $368,580,051 | $184,944,807 | $159,925,813 | $220,699,195 |
| Cash Equivalents | $189,736,467 | $51,371,181 | $4,673,507 | $19,443,031 |
| Cash Financial | $178,843,584 | $133,573,626 | $155,252,307 | $201,256,164 |
| Non Current Accounts Receivable | - | $3,893,691 | $1,054,710 | - |
| Other Non Current Assets | - | - | - | $1,167,031 |
| Debt | ||||
| Total Debt | $296,090,298 | $249,543,381 | $268,552,384 | $268,123,441 |
| Long Term Debt And Capital Lease Obligation | $113,253,863 | $133,025,482 | $176,361,905 | $190,593,157 |
| Long Term Debt | $111,023,448 | $129,915,644 | $174,428,968 | $189,225,564 |
| Current Debt And Capital Lease Obligation | $182,836,434 | $116,517,899 | $92,190,479 | $77,530,284 |
| Current Debt | $181,747,176 | $115,106,186 | $90,731,205 | $76,322,124 |
| Other Current Borrowings | $181,747,176 | $115,106,186 | $90,731,205 | $76,322,124 |
| Net Debt | - | $60,077,023 | $105,234,361 | $44,848,493 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $393,252,510 | $350,520,167 | $363,399,380 | $362,179,255 |
| Total Non Current Liabilities Net Minority Interest | $147,466,868 | $176,039,749 | $223,682,803 | $230,392,594 |
| Other Non Current Liabilities | $1,799,378 | $938,351 | - | - |
| Non Current Deferred Liabilities | $32,413,627 | $42,075,916 | $44,584,067 | $34,515,269 |
| Non Current Deferred Taxes Liabilities | $0 | $802,848 | $1,577,727 | $1,817,325 |
| Current Liabilities | $245,785,642 | $174,480,418 | $139,716,577 | $131,786,662 |
| Other Current Liabilities | $294,338 | - | - | $422,063 |
| Current Deferred Liabilities | $8,986,420 | $8,089,049 | $5,744,668 | $3,642,428 |
| Payables And Accrued Expenses | $53,668,450 | $49,873,469 | $41,781,429 | $50,191,886 |
| Payables | $35,084,801 | $37,630,940 | $34,590,200 | $44,824,862 |
| Other Payable | $17,071,580 | $22,436,510 | $22,500,523 | $29,459,184 |
| Total Tax Payable | $2,048,996 | $1,439,831 | $1,254,674 | $1,073,704 |
| Accounts Payable | $15,964,224 | $13,754,599 | $10,835,003 | $14,291,974 |
| Tradeand Other Payables Non Current | - | $0 | $2,736,831 | $5,284,167 |
| Interest Payable | - | - | $156,442 | $57,282 |
| Equity | ||||
| Common Stock Equity | $198,088,894 | $39,513,325 | $9,036,074 | $61,119,618 |
| Total Equity Gross Minority Interest | $199,547,122 | $41,004,157 | $10,563,848 | $61,119,618 |
| Stockholders Equity | $198,088,894 | $39,513,325 | $9,036,074 | $61,119,618 |
| Gains Losses Not Affecting Retained Earnings | $-86,201,727 | $-76,364,151 | $-75,448,085 | $-77,549,877 |
| Other Equity Adjustments | $-59,417,306 | $-57,508,748 | $-55,553,377 | $-53,727,826 |
| Retained Earnings | $-1,048,925,221 | $-863,054,477 | $-802,417,196 | $-663,977,279 |
| Long Term Equity Investment | $4,940,026 | $4,893,213 | $2,542,251 | $2,381,323 |
| Other | ||||
| Ordinary Shares Number | $55,834,657 | $47,145,611 | $43,402,314 | $39,661,683 |
| Share Issued | $55,834,657 | $47,145,611 | $43,402,314 | $39,661,683 |
| Tangible Book Value | $184,534,110 | $24,453,650 | $-7,436,660 | $44,817,683 |
| Invested Capital | $490,859,519 | $284,535,154 | $274,196,248 | $326,667,306 |
| Working Capital | $194,550,113 | $45,997,875 | $61,321,078 | $112,969,397 |
| Capital Lease Obligations | $3,319,673 | $4,521,552 | $3,392,211 | $2,575,753 |
| Total Capitalization | $309,112,343 | $169,428,969 | $183,465,043 | $250,345,182 |
| Minority Interest | $1,458,227 | $1,490,832 | $1,527,774 | $0 |
| Foreign Currency Translation Adjustments | $-26,784,421 | $-18,855,403 | $-19,894,708 | $-23,822,051 |
| Treasury Stock | $442,852 | $1,196 | $3,193,294 | $3,971,164 |
| Additional Paid In Capital | $1,333,620,407 | $978,901,144 | $890,065,185 | $806,591,017 |
| Capital Stock | $38,288 | $32,006 | $29,464 | $26,921 |
| Common Stock | $38,288 | $32,006 | $29,464 | $26,921 |
| Non Current Deferred Revenue | $32,413,627 | $41,273,069 | $43,006,340 | $32,697,944 |
| Long Term Capital Lease Obligation | $2,230,415 | $3,109,838 | $1,932,936 | $1,367,593 |
| Current Deferred Revenue | $8,986,420 | $8,089,049 | $5,744,668 | $3,642,428 |
| Current Capital Lease Obligation | $1,089,258 | $1,411,714 | $1,459,274 | $1,208,160 |
| Current Accrued Expenses | $18,583,649 | $12,242,529 | $7,191,230 | $5,367,024 |
| Investments And Advances | $5,538,273 | $5,063,863 | $2,834,046 | $2,771,529 |
| Investmentsin Joint Venturesat Cost | $4,940,026 | $4,893,213 | $2,542,251 | $2,381,323 |
| Goodwill | $3,693,279 | $3,693,279 | $3,693,279 | $3,693,279 |
| Net PPE | $124,023,508 | $135,482,034 | $143,165,322 | $97,218,896 |
| Accumulated Depreciation | $-42,928,568 | $-33,119,409 | $-22,558,553 | $-10,555,323 |
| Gross PPE | $166,952,076 | $168,601,443 | $165,723,875 | $107,774,219 |
| Leases | $9,083,485 | $6,616,464 | $4,369,896 | $1,157,758 |
| Construction In Progress | $343,095 | $1,135,772 | $1,916,634 | $6,101,223 |
| Machinery Furniture Equipment | $27,905,536 | $27,421,105 | $26,900,930 | $23,213,783 |
| Buildings And Improvements | $125,830,364 | $129,469,501 | $128,408,809 | $73,004,844 |
| Land And Improvements | $3,789,596 | $3,958,601 | $4,127,606 | $4,296,611 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-625,168 | $0 | - | - |
| Finished Goods | $1,110,795 | $577,458 | $1,656,845 | $659,567 |
| Work In Process | $3,794,532 | $409,201 | $761,120 | $753,492 |
| Investment Properties | - | - | $0 | $53,157,996 |
| Other Properties | - | - | - | $97,024,017 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-10-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-179,728,241 | $-20,287,457 | $-117,095,058 | $-133,241,299 |
| Operating Activities | ||||
| Operating Cash Flow | $-175,604,674 | $-16,654,751 | $-108,593,369 | $-97,800,691 |
| Cash Flow From Continuing Operating Activities | $-175,604,674 | $-16,654,751 | $-108,593,369 | $-97,800,691 |
| Operating Gains Losses | $1,475,427 | $-951,662 | $-826,030 | $-2,770,034 |
| Investing Activities | ||||
| Capital Expenditure | $-4,123,568 | $-3,632,706 | $-8,501,690 | $-35,440,608 |
| Investing Cash Flow | $-149,569,557 | $-54,146,599 | $3,278,693 | $-57,523,255 |
| Cash Flow From Continuing Investing Activities | $-149,569,557 | $-54,146,599 | $3,278,693 | $-57,523,255 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-1,351,440 | $0 | $-885,854 | $-4,004,666 |
| Issuance Of Capital Stock | $344,725,695 | $79,857,017 | $70,306,151 | $0 |
| Financing Cash Flow | $379,901,877 | $47,077,113 | $55,151,056 | $92,618,824 |
| Cash Flow From Continuing Financing Activities | $379,901,877 | $47,077,113 | $55,151,056 | $92,618,824 |
| Net Other Financing Charges | $-1,754,061 | $-1,986,629 | $1,538,991 | - |
| Cash Dividends Paid | $0 | $0 | $0 | $0 |
| Net Common Stock Issuance | $343,374,254 | $79,857,017 | $69,420,297 | $-4,004,666 |
| Common Stock Issuance | $344,725,695 | $79,857,017 | $70,306,151 | $0 |
| Other | ||||
| Repayment Of Debt | $-139,646,881 | $-101,890,907 | $-144,604,854 | $-10,131,764 |
| Issuance Of Debt | $185,601,682 | $80,153,598 | $142,607,157 | $114,207,918 |
| End Cash Position | $178,843,584 | $133,573,626 | $155,252,307 | $201,256,164 |
| Beginning Cash Position | $133,573,626 | $155,252,307 | $201,256,164 | $255,284,908 |
| Effect Of Exchange Rate Changes | $-9,457,689 | $2,045,556 | $4,159,762 | $8,676,378 |
| Changes In Cash | $54,727,647 | $-23,724,237 | $-50,163,619 | $-62,705,122 |
| Interest Paid Cff | $-7,673,716 | $-9,056,863 | $-13,811,731 | $-7,455,505 |
| Proceeds From Stock Option Exercised | $598 | $897 | $1,196 | $2,842 |
| Common Stock Payments | $-1,351,440 | $0 | $-885,854 | $-4,004,666 |
| Net Issuance Payments Of Debt | $45,954,801 | $-21,737,309 | $-1,997,697 | $104,076,154 |
| Net Long Term Debt Issuance | $45,954,801 | $-21,737,309 | $-1,997,697 | $104,076,154 |
| Long Term Debt Payments | $-139,646,881 | $-101,890,907 | $-144,604,854 | $-10,131,764 |
| Long Term Debt Issuance | $185,601,682 | $80,153,598 | $142,607,157 | $114,207,918 |
| Net Investment Purchase And Sale | $-138,963,683 | $-46,697,675 | $14,769,525 | $-19,443,031 |
| Purchase Of Investment | $-138,963,683 | $-46,697,675 | $0 | $-19,443,031 |
| Net Business Purchase And Sale | $-6,482,307 | $-3,816,218 | $-2,991,236 | $-2,991,236 |
| Purchase Of Business | $-6,482,307 | $-3,816,218 | $-2,991,236 | $-2,991,236 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-1,605,695 | $-5,036,493 |
| Purchase Of Intangibles | $0 | $0 | $-1,605,695 | $-5,036,493 |
| Net PPE Purchase And Sale | $-4,123,568 | $-3,632,706 | $-6,893,901 | $-30,052,495 |
| Sale Of PPE | $0 | $0 | $2,094 | $351,620 |
| Purchase Of PPE | $-4,123,568 | $-3,632,706 | $-6,895,995 | $-30,404,115 |
| Taxes Refund Paid | $-4,337 | $0 | $0 | $0 |
| Change In Working Capital | $-21,462,564 | $16,596,272 | $-1,367,892 | $15,616,194 |
| Change In Other Working Capital | $-2,622,865 | $596,752 | $11,223,714 | $-646,705 |
| Change In Other Current Assets | $4,155,424 | $-7,321,049 | $-531,243 | $4,394,125 |
| Change In Payables And Accrued Expense | $19,231,102 | $14,661,093 | $3,807,693 | $12,285,902 |
| Change In Payable | $19,231,102 | $14,661,093 | $3,807,693 | $12,285,902 |
| Change In Account Payable | $2,209,626 | $2,919,596 | $-3,456,971 | $3,693,877 |
| Change In Prepaid Assets | $-12,912,715 | $-2,156,830 | $-1,172,714 | $466,184 |
| Change In Inventory | $-3,918,668 | $1,431,306 | $-1,004,906 | $-825,282 |
| Change In Receivables | $-25,394,842 | $9,385,002 | $-13,690,437 | $-58,030 |
| Changes In Account Receivables | $-25,394,842 | $9,385,002 | $-13,690,437 | $-58,030 |
| Other Non Cash Items | $12,401,364 | $9,627,292 | $14,366,456 | $7,863,958 |
| Stock Based Compensation | $3,121,953 | $3,129,431 | $4,711,645 | $3,306,063 |
| Unrealized Gain Loss On Investment Securities | $169,603 | $124,435 | $104,544 | $1,460,471 |
| Asset Impairment Charge | $625,168 | $0 | $0 | - |
| Depreciation Amortization Depletion | $12,934,103 | $13,934,521 | $13,938,410 | $9,409,679 |
| Depreciation And Amortization | $12,934,103 | $13,934,521 | $13,938,410 | $9,409,679 |
| Amortization Cash Flow | $1,504,891 | $1,622,895 | $1,555,293 | $1,463,013 |
| Amortization Of Intangibles | $1,504,891 | $1,622,895 | $1,555,293 | $1,463,013 |
| Depreciation | $11,429,212 | $12,311,627 | $12,383,117 | $7,946,666 |
| Earnings Losses From Equity Investments | $-46,962 | $42,027 | $-160,928 | $41,578 |
| Net Foreign Currency Exchange Gain Loss | $1,519,697 | $-1,001,167 | $-242,440 | $404,265 |
| Gain Loss On Sale Of PPE | $2,692 | $7,478 | $-598 | $-309,294 |
| Net Income From Continuing Operations | $-184,865,389 | $-59,115,041 | $-139,520,501 | $-132,687,023 |
| Sale Of Investment | - | - | $14,769,525 | $0 |
| Gain Loss On Investment Securities | - | - | $-422,063 | $-2,906,584 |
| Change In Other Current Liabilities | - | - | - | $0 |
Fetched: 2026-10-18